These ASX blue chips now look too cheap to ignore

These blue chips could be worth a closer look after sharp declines.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It is not often that high-quality blue chip shares trade at discounted valuations. These are typically businesses with strong competitive advantages, global earnings, and long track records of performance.

But from time to time, even the best companies fall out of favour.

Right now, a handful of ASX blue chips appear to be in that position. Here are three that could be worth a closer look.

A man looking at his laptop and thinking.

Image source: Getty Images

CSL Ltd (ASX: CSL)

CSL is widely regarded as one of Australia's highest-quality companies, but the biotech giant's shares have come under pressure in recent times.

This has been driven by earnings misses, margin pressures, a tough operating environment, and leadership changes.

However, these are largely transitional issues rather than structural ones.

CSL still operates a global leader in plasma therapies and vaccines, with strong demand drivers linked to ageing populations and rising healthcare needs. As plasma collection normalises and efficiencies improve, there is potential for margins to recover.

For long-term investors, this could be one of those rare opportunities to buy a premium healthcare business at a more reasonable price.

Cochlear Ltd (ASX: COH)

Another ASX blue chip that could be looking attractive is Cochlear.

Short-term concerns around softer demand have weighed on sentiment. But this does not change the underlying demand for hearing solutions.

Cochlear benefits from a powerful structural tailwind. Hearing loss is a growing global issue, and access to treatment is still underpenetrated in many regions.

The company also enjoys a strong competitive position, supported by technology leadership and a global distribution network.

For investors willing to look beyond near-term noise, Cochlear's long-term growth story appears firmly intact.

Treasury Wine Estates Ltd (ASX: TWE)

A third ASX blue chip that may be undervalued is Treasury Wine Estates.

The company has faced a number of challenges in recent years, including shifting consumer preferences and disruptions to key export markets. These issues have weighed on its share price and created uncertainty around its outlook.

However, Treasury Wine is in the process of reshaping its portfolio.

The focus is increasingly on premium and luxury brands, where margins are higher and demand tends to be more resilient. This shift is helping the company reduce reliance on lower-margin products and improve the quality of its earnings.

In addition, improving trade dynamics and stabilising conditions in key markets could provide a tailwind over time.

While not without risks, Treasury Wine Estates could offer a compelling turnaround opportunity for patient investors.

Motley Fool contributor James Mickleboro has positions in CSL, Cochlear, and Treasury Wine Estates. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Cochlear, and Treasury Wine Estates. The Motley Fool Australia has positions in and has recommended Treasury Wine Estates. The Motley Fool Australia has recommended CSL and Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Blue Chip Shares

Workers inspecting a gas pipeline.
Dividend Investing

This overlooked ASX stock has raised its dividend 20 years in a row

20 years of consistent dividend growth is just the tip of the iceberg for this quality business.

Read more »

Person handing out $50 notes, symbolising ex-dividend date.
Blue Chip Shares

Where I'd invest $10,000 into ASX 200 dividend shares right now

These businesses look like compelling buys today.

Read more »

A smiling woman with a handful of $100 notes, indicating strong dividend payments
Retail Shares

3 ASX retail shares exposed to a drop in consumer spending

Which stocks could be most impacted by a drop in consumer spending?

Read more »

A target on a red background surrounded by white arrows pointing to it.
Blue Chip Shares

2 high-quality ASX 200 shares experts rate as buys

Experts say these businesses are undervalued.

Read more »

Man with virtual white circles on his eye and AI written on top, symbolising artificial intelligence.
Blue Chip Shares

Why this ASX 200 blue-chip share could be an AI winner

Some companies sell AI tools. Others may create value by applying them across large customer bases and complex operations.

Read more »

A bland looking man in a brown suit opens his jacket to reveal a red and gold superhero dollar symbol on his chest.
Blue Chip Shares

1 ASX blue chip stock I'd consider buying with the ASX 200 around 8,700

This healthcare business has exposure to a large underdiagnosed market, strong recent momentum, and a growing digital ecosystem.

Read more »

A young woman sits with her hand to her chin staring off to the side thinking about her investments.
Blue Chip Shares

Should I buy CBA and Qantas shares this month?

These two ASX 200 shares offer very different opportunities, but both could be worth considering for long-term investors in May.

Read more »

A young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Blue Chip Shares

2 ASX 200 shares I'd buy and 2 I'd sell this month

Quality is important, but price is too. That's why I would be selective across the ASX 200 rather than buying…

Read more »